S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Biocon Collaborates with Advaxis for ‘ADXS-HPV’ A Novel Cancer Immunotherapy (2014/1/22)|
|Advaxis Signs Exclusive Licensing Agreement for Development and Commercialization of ADXS-HPV in Asia ()|
|Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer (2014/3/18)|
|Advaxis Reports Final 18-Month Survival Data for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 Society for Immunotherapy of Cancer Annual Meeting ()|
|Advaxis Announces Initiation of Phase 1/2 Trial of ADXS-HPV in Head and Neck Cancer Conducted by Icahn School of Medicine at Mount Sinai (2013/11/20)|
|Advaxis Engages SynCo Bio Partners for Manufacturing of ADXS-HPV, Its Lead Cancer Immunotherapy Program (2014/2/11)|
|Advaxis Cancer Immunotherapy Featured on CNN (2014/3/3)|
|Advaxis’ ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Head and Neck Cancer ()|
|Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer (2014/3/17)|
|Advaxis Announces First Patient Dosed with ADXS-HPV in Head and Neck Cancer Study ()|
Click above to view more mutual fund data and stats for adxs - Advaxis Incorporated.